Related Experiment Videos
Bladder cancer: current optimal intravesical treatment.
Donald L Lamm1, William R McGee, Kaye Hale
1BCG Oncology, PC, Phoenix, AZ, USA.
Urologic Nursing
|November 22, 2005
Summary
Superficial bladder cancer treatment varies by risk. Low-risk tumors receive chemotherapy, while intermediate and high-risk tumors benefit from bacillus Calmette-Guerin (BCG) immunotherapy, with options for rescue therapy if initial treatment fails.
Area of Science:
- Urology
- Oncology
Background:
- Superficial bladder cancer necessitates risk stratification for effective treatment.
- Recurrence is a significant concern following surgical intervention.
Purpose of the Study:
- To outline treatment strategies for superficial bladder cancer based on risk stratification.
- To discuss the role of chemotherapy and bacillus Calmette-Guerin (BCG) immunotherapy.
Main Methods:
- Categorization of tumors into low, intermediate, and high-risk groups.
- Review of treatment modalities including intravesical chemotherapy and BCG immunotherapy.
- Exploration of salvage treatment options for BCG-refractory cases.
Main Results:
- Low-risk tumors are managed with single-dose intravesical chemotherapy.
- Intermediate-risk tumors may require chemotherapy or immunotherapy.
- High-risk tumors are best treated with intravesical BCG, often with maintenance schedules.
- BCG immunotherapy toxicity can be managed with dose reduction.
- Patients failing BCG can be treated with BCG plus interferon alfa or radical cystectomy.
Conclusions:
- Treatment selection for superficial bladder cancer is guided by risk stratification.
- Intravesical chemotherapy and BCG immunotherapy are primary treatment options.
- Salvage options exist for patients who do not respond to initial BCG therapy.